NCT03572777View on ClinicalTrials.gov

Comparison of Therapy in Treatment of Patients With Helicobacter Pylori Infection: Concomitant Versus Hybrid Therapy.

NACompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

October 1, 2019

Study Completion Date

October 15, 2019

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Concomitant therapy

Amoxicillin ('Amoksicilin') 1 g bid 14 days.

DRUG

Concomitant therapy

Clarithromycin ('Makcin') 500 mg bid for 14 days

DRUG

Concomitant therapy

Metronidazole ('Medazol') 500 mg bid for 14 days

DRUG

Concomitant therapy

Esomeprazole ('Emanera') 40 mg bid for 14 days

DRUG

Hybrid therapy

Amoxicillin ('Amoksicilin') 1 g bid 14 days

DRUG

Hybrid therapy

Esomeprazole ('Emanera') 40 mg bid for 14 days

DRUG

Hybrid therapy

Clarithromycin ('Makcin') 500 mg bid for the last 7 days

DRUG

Hybrid therapy

Metronidazole ('Medazol') 500 mg bid for the last 7 days

Trial Locations (1)

21210

University Hospital Centre Split, Split

All Listed Sponsors
collaborator

University Hospital of Split

OTHER

collaborator

University of Split, School of Medicine

OTHER

lead

Antonio Mestrovic

OTHER

NCT03572777 - Comparison of Therapy in Treatment of Patients With Helicobacter Pylori Infection: Concomitant Versus Hybrid Therapy. | Biotech Hunter | Biotech Hunter